Capex
Flow – sum over the period · $M
Q2 2025
287a$M
derived
All values (42)
| Period | Value ($M) | Status |
|---|---|---|
| Q2 2026 | 441 | derived |
| Q1 2026 | 271 | reported |
| Q4 2025 | 427 | derived |
| Q3 2025 | 357 | derived |
| Q2 2025 | 287 | derived |
| Q1 2025 | 272 | reported |
| Q4 2024 | 305 | derived |
| Q3 2024 | 223 | derived |
| Q2 2024 | 184 | derived |
| Q1 2024 | 148 | reported |
| Q4 2023 | 180 | derived |
| Q3 2023 | 126 | derived |
| Q2 2023 | 114 | derived |
| Q1 2023 | 89 | reported |
| Q4 2022 | 112 | derived |
| Q3 2022 | 106 | derived |
| Q2 2022 | 99 | derived |
| Q1 2022 | 137 | reported |
| Q4 2021 | 148 | derived |
| Q3 2021 | 162 | derived |
| Q2 2021 | 150 | derived |
| Q1 2021 | 113 | reported |
| Q4 2020 | 87 | derived |
| Q3 2020 | 65 | derived |
| Q2 2020 | 50 | derived |
| Q1 2020 | 45 | reported |
| Q4 2019 | 36 | derived |
| Q3 2019 | 29 | derived |
| Q2 2019 | 38 | derived |
| Q1 2019 | 33 | reported |
| Q4 2018 | 28 | derived |
| Q3 2018 | 23 | derived |
| Q2 2018 | 23 | derived |
| Q1 2018 | 20 | reported |
| Q4 2017 | 16 | derived |
| Q3 2017 | 13 | derived |
| Q2 2017 | 16 | derived |
| Q1 2017 | 10 | reported |
| Q4 2016 | 13 | derived |
| Q3 2016 | 23 | derived |
| Q2 2016 | 18 | derived |
| Q1 2016 | 15 | reported |
CSV with all sources · Technical ID: capex
More metrics for MercadoLibre
Income statement
Balance sheet
Debt and interest
Sources & calculation
- Value
- $287M (derived)
- Period
- Q2 2025, ended Jun 30, 2025 · quarterly value (3 months, not cumulative)
- Calculation
- Q2 = 6 months kumuliert − 3 months kumuliert = 559M − 272M = $287M (us-gaap:PaymentsToAcquireProductiveAssets; 6-Monats-Wert aus 0001099590-26-000023, Vorperiode aus dem vorherigen 10-Q)
- Source
- 10-Q, filed Aug 6, 2026 · 0001099590-26-000023
- Location
- us-gaap:PaymentsToAcquireProductiveAssets
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $287M | Aug 6, 2026 | 10-Q 0001099590-26-000023 | derived · confidence 1. · current |